Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 9/20 | 0.42 |
| ▸ | BACE1 | P56817 | 2/20 | 0.41 |
| ▸ | F10 | P00742 | 1/20 | 0.41 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.40 |
| ▸ | BCL2 | P10415 | 1/20 | 0.39 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.39 |
| ▸ | WDR5 | P61964 | 2/20 | 0.39 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.38 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.38 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.38 |
| ▸ | ACLY | P53396 | 1/20 | 0.37 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12117807 | 0.91 | BACE1 (0.41) | HDAC1BACE1F10LRRK2BCL2 | |
| SCHEMBL1315504 | 0.91 | HDAC1 (0.46) | HDAC1BACE1BCL2BCL2L1WDR5 | |
| SCHEMBL1316253 | 0.90 | HDAC1 (0.44) | HDAC1BACE1F10WDR5HDAC2 | |
| SCHEMBL1315634 | 0.89 | WDR5 (0.49) | HDAC1BACE1WDR5HDAC2HDAC3 | |
| SCHEMBL1316547 | 0.89 | HDAC1 (0.45) | HDAC1BACE1F10 | |
| SCHEMBL1327669 | 0.88 | HDAC1 (0.42) | HDAC1BACE1WDR5HDAC2HDAC3 | |
| SCHEMBL1327665 | 0.88 | HDAC1 (0.42) | HDAC1BACE1WDR5HDAC2HDAC3 | |
| SCHEMBL12117799 | 0.87 | ACLY (0.47) | HDAC1F10LRRK2HDAC2ACLY | |
| SCHEMBL12117816 | 0.87 | BACE1 (0.44) | HDAC1BACE1WDR5HDAC2HDAC3 | |
| Hydrochloric Acid SCHEMBL1316458 | 0.86 | ACLY (0.46) | HDAC1F10LRRK2HDAC2ACLY |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102333757-B | N-acyl anthranilic acid derivative or salt thereof | TOYAMA CHEMICAL CO LTD | 2014-11-26 | — | — | CN | disclosed |
| US-8492582-B2 | N-acyl anthranilic acid derivative or salt thereof | TOYAMA CHEMICAL CO., LTD. (JP) | 2013-07-23 | — | — | US | disclosed |
| US-8492582-B2 | N-acyl anthranilic acid derivative or salt thereof | TOYAMA CHEMICAL CO., LTD. (JP) | 2013-07-23 | — | — | US | disclosed |
| US-20110275797-A1 | N-ACYL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF | TOYAMA CHEMICAL CO., LTD. (JP) | 2011-11-10 | — | — | US | disclosed |
| US-20110275797-A1 | N-ACYL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF | TOYAMA CHEMICAL CO., LTD. (JP) | 2011-11-10 | — | — | US | disclosed |
| EP-2385036-A1 | N-ACYL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF | Toyama Chemical Co., Ltd. (JP) | 2011-11-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110275797-A1 | N-ACYL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF | COL14A1, COL2A1, COL1A1 | HDAC1 73/4885BACE1 3622/4885F10 205/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.